PATENT CLAIM ANALYSIS

Application Number: 15765232
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["548", "400000"]

Abstract:
Disclosed are compounds based on dolastatins, drug-conjugates, methods of preparing drug-conjugates, and uses thereof. Also disclosed are pharmaceutical compositions and methods of treatment. The compounds and drug-conjugates disclosed herein can be used to treat diseases such as bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, lung cancer, melanoma, non-Hodgkin lymphoma, glioblastoma, pancreatic cancer, prostate cancer, and thyroid cancer.

Claim (Index 20):
The compound of  claim 5 , wherein the targeting moiety binds to one or more tumor-associated antigens or cell surface receptors selected from the group consisting of CD19, CD22, CD30, CD33, CD56, CD70, CD79b, CD74, CD138, HER2, GPNMB, PSMA, SLC44A4, CA6, CA-IX, Mesothelin, CD66e, CEACAM5, and Nectin-4, or the targeting moiety is a protein ligand, a protein scaffold, a peptide, cysteine-engineered antibody, antibody-like protein, monoclonal antibody (mAB), an antibody fragment, surrogate, or variant.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 90.0
- Lexical Diversity: 1.77778
- Patent Class: 548.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14401318', '14843520', '15581749', '15557703', '13513982']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.796895407242901
- 35 USC 102 Novelty (BERT): 0.5146403503604274
- Combined Prediction Score: 0.7686699015546536
- Mean Citation Score: 295.580128
- Max Citation Score: 303.1212
- Similarity Product: 201.34224555966853

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test